AstraZeneca has announced positive high-level results from its Phase III KALOS and LOGOS trials, showing significant promise ...

Novo Nordisk NVO and Jazz Pharmaceuticals JAZZ reported their first-quarter results. AstraZeneca’s AZN late-stage asthma ...

Despite lower-than-expected first-quarter revenues and a guidance cut for 2025, NVO stock price rose post its earnings ...

Breztri Aerosphere, a triple inhaled therapy, met its primary endpoint of lung function improvement in adults and adolescents ...

The replicate confirmatory KALOS and LOGOS trials evaluated BGF in participants with severe asthma inadequately controlled with standard of care.

The single-inhaler demonstrated a meaningful improvement in lung function in the Phase III KALOS and LOGOS studies.

AstraZeneca has announced the Positive high-level results from the Phase III KALOS and LOGOS trials in patients with ...